Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Darma Agung Harmoni Economics: International Journal of Economics and Accounting
Ramly Siahaan
Universitas Darma Agung
Humanities Civil Engineering, Building, Construction & Architecture Computer Science & IT Decision Sciences, Operations Research & Management Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Library & Information Science Materials Science & Nanotechnology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
DAMPAK COVID-19 TERHADAP HARGA SAHAM DAN VOLUME TRANSAKSI SAHAM PADA PERUSAHAAN FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA Hotriado Harianja; Yannuke P Siahaan; Ramly Siahaan; Kinanti Siahaan
Jurnal Darma Agung Vol 30 No 1 (2022): APRIL
Publisher : Lembaga Penelitian dan Pengabdian kepada Masyarakat Universitas Darma Agung (LPPM_UDA)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46930/ojsuda.v30i1.1411

Abstract

Setelah diumumkanya pertama sekali adaya kasus covid -19 pada tanggal 2 Maret 2020 banyak mempengaruhi tatanan kehidupan bahkan perekonomian di Indonesia termasuk perusahaan besar maupun kecil. Penelitian ini bertujuan untuk mengetahui apakah terdapat perbedaan yang significant antara harga saham dan volume transaksi saham, sebelum dan sesudah terjadi Pandem covid -19 pada perusahaan Farmasi Yang terdatar diBursa Efek Indonesia. Jumlah Sampel yang diambil sebanyak 9 Perusahaan yang diambil melalui metode Purpose Sampling dengan data obsevasi selama 6 Bulan sebelum dan sesudah pengumuman Pandemi Covid-19 yakni Maret 2020.Harga saham dan volume transksi saham diukur dengan harga penutupan setiap akhir bulan melalui siutus Yahoo finance. Analisis data penelitian dengan menggunakan uji wilcoxon . Hasil uji menunjukkan tidak terdapat perbedaan yang signifikan antara hargA saham sebelum Pandemi dengan sesudah pandemic covid – 19 pada perusahaan farmasi yang terdaftar di Bursa Efek Indonesia yang dilihat dari nilai Asyimp sig 0,611> 0,05 Uutuk volume transaksi saham dilihat dari nilai Asyimp sig bernilai 0,000 lebih kecil dari 0,05 (0.000 < 0,05) disimpulkan bahwa terdapat Perbedaan yang sgnifikat antara volume transksi saham sebelum Pandemi dengan sesudah pandemic covid – 19 pada perusahaan farmasi yang terdaftar di Bursa Efek Indonesia yakni mengalami penurunan volume transaksi saham.
Analysis of Bankruptcy Prediction in State-Owned Enter-prises in the Pharmaceuticals Sector Santy Aji Sitohang; Wie Shi Wudjud; Efri Elsridayani Purba; Roris Tua Pandiangan; Yanuke Patricia Siahaan; Ramly Siahaan
Harmoni Economics: International Journal of Economics and Accounting Vol. 2 No. 4 (2025): November: Harmoni Economics: International Journal of Economics and Accounting
Publisher : International Forum of Researchers and Lecturers

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70062/harmonieconomics.v2i4.436

Abstract

Operational performance of two state-owned pharmaceutical companies has been in the public spotlight in recent years. Poor financial conditions have caused both companies to experience net losses for years. The risk of bankruptcy becomes a serious threat if the fundamental problems of these two state-owned pharmaceutical companies are not successfully addressed. This study was conducted to determine whether PT. Kimia Farma Tbk and PT. Indofarma Tbk are likely to go bankrupt between 2021-2024 and to analyze the factors that could lead to bankruptcy. This study used a descriptive quantitative approach. Data were analyzed using Springate, Grover, and Zmijewski models to detect bankruptcy. Springate model predicted PT. Kimia Farma Tbk would be in the bankruptcy category from 2021-2024. Grover and Zmijewski model analysis showed that PT. Kimia Farma Tbk was in the healthy category from 2021-2022, then entered the bankruptcy category from 2023-2024. The potential for bankruptcy is influenced by poor liquidity, the company's reliance on debt to finance assets, unproductive asset management, and net losses. The condition of PT. Indofarma Tbk is categorized as bankrupt from 2021-2024 based on the Zmijewski and Springate models. The Grover model predicts PT. Indofarma Tbk will be healthy in 2021 and will then go bankrupt in 2022-2024. Indications of bankruptcy are influenced by declining sales and assets, debt exceeding assets, liquidity difficulties, and a continuing trend of losses.
Co-Authors Efri Elsridayani Purba Hotriado Harianja Kinanti Siahaan Roris Tua Pandiangan SANTY AJI SITOHANG Wie Shi Wudjud Yannuke P Siahaan Yanuke Patricia Siahaan